FDA Wants Clarity From Valeant

Valeant Pharmaceuticals International (VRX Quote) said Tuesday that it received conditional approval from the Food and Drug Administration to sell a new treatment for Parkinson's disease.

Put another way, before regulators will allow the drug to be sold, they want some type of further information.

The FDA is seeking "additional clarification on specific issues previously addressed by Valeant," the company said. "Valeant plans to meet with the FDA, promptly as they have requested, to discuss and resolve these matters." ...